Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study
Author:
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/article/10.1007/s00280-018-3587-7/fulltext.html
Reference20 articles.
1. Bruno R, Mercier F, Claret L (2014) Evaluation of tumor-size response metrics to predict survival in oncology clinical trials. Clin Pharmacol Ther 95:386–393
2. Venkatakrishnan K, Friberg LE, Ouellet D et al (2015) Optimizing oncology therapeutics through quantitative clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther 97:37–54
3. Claret L, Girard P, Hoff PM et al (2009) Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103–4108
4. Claret L, Gupta M, Han K et al (2013) Evaluation of tumor size response metrics to predict overall survival in western and Chinese patients with first line metastatic colorectal cancer. J Clin Oncol 31:2110–2114
5. Sharma MR, Gray E, Goldberg RM et al (2015) Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. J Clin Oncol 33:36–41
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer;European Journal of Cancer;2024-08
2. Oral Delivery of Gemcitabine-Loaded Glycocholic Acid-Modified Micelles for Cancer Therapy;ACS Nano;2023-09-17
3. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework;CPT: Pharmacometrics & Systems Pharmacology;2021-08-04
4. Which factors matter the most? Revisiting and dissecting antibody therapeutic doses;Drug Discovery Today;2021-08
5. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer;British Journal of Clinical Pharmacology;2021-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3